Screening for bladder cancer using urine-based tumor markers

Minerva Urologica e Nefrologica

Volumn 60, Issue 4, 2008, Pages 247-253

  Svatek, R S ^a   Lotan, Y ^b   Karakiewizc, P I ^c   Shariat, S F ^d,e  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^c UNIVERSITÉ DE MONTRÉAL   (Canada)

^d MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^e Memorial Sloan Kettering ^*  (United States)

Author keywords

Screeening; Tumor markers, biological; Urinary bladder neoplasms, diagnosis

Indexed keywords

BIOLOGICAL MARKER; NUCLEAR MATRIX PROTEIN 22; TELOMERASE; TUMOR MARKER;

BLADDER CANCER; CANCER RESEARCH; CANCER SCREENING; HEMATURIA; HUMAN; REVIEW; SENSITIVITY ANALYSIS;

ANTIGENS, NEOPLASM; EVIDENCE-BASED MEDICINE; HEMATURIA; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; MASS SCREENING; NUCLEAR PROTEINS; SENSITIVITY AND SPECIFICITY; TUMOR MARKERS, BIOLOGICAL; URINARY BLADDER NEOPLASMS;

EID: 57649135074     PISSN: 03932249     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (26)

1. Jemal A, Siegel B. Ward E, Hao Y, Xu J, Murray T et al. Cancer Statistics 2008. 2008;58:71-96.
2. th edition. Walsh AR PC, Vaughn ED, Wein AJ et al. Saunders 2002;4:2785.
3. Botteman MF, Pashos CL, Redaelli A, Laskin B, Hauser R. The health economics of bladder cancer: a comprehensive review of the published literature. Pharmacoeconomics 2003;21:1315-30.
4. th edition. In: Walsh AR PC, Vaughn ED, Wein AJ et al. Sauders 2002;4:2732-84.
5. Chan EC. Promoting an ethical approach to unproven screening imaging tests. J Am Coll Radiol 2005;2:311-20.
6. NCI: NCI cancer screening overview, vol. 2007, 2007.
7. Britton JP, Dowell AC, Whelan P, Harris CM. A community study of bladder cancer screening by the detection of occult urinary bleeding. J Urol 1992;148:788-90.
8. Messing EM, Young TB, Hunt TB, Newton MA, Bram LL, Vaillancourt A et al. Hematuria home screening: repeat testing results. J Urol 1995;154:57-61.
9. Messing EM, Madeb R, Young T, Gilchrist KW, Bram L, Greenberg EB et al. Long-term outcome of hematuria home screening for bladder cancer in men. Cancer 2006;107:2173-9.
10. Whelan P, Britton JP, Dowell AC. Three-year follow-up of bladder tumours found on screening. Br J Urol 1993;72:893-6.
11. Hedelin H, Jonsson K, Salomonsson K, Boman H. Screening for bladder tumours in men aged 60-70 years with a bladder tumour marker (UBC) and dipstick-detected baematuria using both white-light and fluorescence cystoscopy. Scand J Urol Nephrol 2006;40:26-30.
12. Hellsten S, Berge T, Wehlin L. Unrecognized renal cell carcinoma Clinical and pathological aspects. Scand J Urol Nephrol 1981;15:273-8.
13. Kishi K, Hirota T, Matsumoto K, Kakizoe T, Murase T, Fujita J. Carcinoma of the bladder: a clinical and pathological analysis of 87 autopsy cases. J Urol 1481;125:36-9.
14. rd et al. Bladder tumor markers beyond cytology: International Consensus Panel on bladder tumor makers. Urology 2005;66:35-63.
15. Lotan Y, Roehrborn CG. Sensitivity and specificity of commonly available bladder tumor markers versus cytology: results of a comprehensive literature review and meta-analyses. Urology 2003;61:109-18.
16. Nielsen ME, Gonzalgo ML, Schoenberg MP, Getzenberg RH. Toward critical evaluation of the role(s) of molecule biomarkers in the management of bladder cancer. World J Urol 2006;24:499-508.
17. Chao D, Freedland SJ, Pantuck AJ, Zisman A, Belldegrun AS. Bladder cancer 2000: molecular markers for the diagnosis of transitional cell carcinoma. Rev Urol 2001;3:85-93.
18. Nasuti JF, Gomella LG, Ismial M, Bibbo M. Utility of the BTA stat test kit for bladder cancer screening. Diagn Cytopathol 1999;21:27-9.
19. Grossman HB, Messing E, Soloway M, Tomera K, Katz G, Berger Y et al. Detection of bladder cancer using a point-of-care proteomic assay. JAMA 2005;293:810-6.
20. Junker K, Fritsch T, Hartmann A, Schulze W, Schubert J. Multicolor fluorescence in situ hybridization (M-FISH) on cells from urine for the detection of bladder cancer. Cytogenet Genome Res 2006;114:279-83.
21. Kruger S, Mess F, Bohle A, Feller AC. Numerical aberrations of chromosome 17 and the 9p21 locus are independent predictors of tumor recurrence in non-invasive transitional cell carcinoma of the urinary bladder. Int J Oncol 2003;2:41-8.
22. Sokolova IA, Halling KC, Jenkins RB, Burkhardt HM, Meyer RG, Seelig SA et al. The development of a multitarget, multicolor fluorescence in situ hybridization assay for the detection of urothelial carcinoma in urine. J Mol Diagn 2000;2:116-23.
23. Placer J, Espinet B, Salido M, Sole F, Gelabert-Mas A. Clinical utility of a multiprobe FISH assay in voided urine specimens for the detection of bladder cancer and its recurrences, compared with urinary cytology. Fur Urol 200;42:547-52.
24. van Rhijn BW, van der Poel HG, van der Kwast TH. Urine markers for bladder cancer surveillance: a systematic review. Fur Urol 2005;47:736-48.
25. Sarosdy MF, Kahn PR, Ziffer MD, Love WR, Barkin J, Abara EO et al. Use of a multitarget fluorescence in situ hybridization assay to diagnose bladder cancer in patients with hematuria. J Urol 2006;176:44-7.
26. Mian C, Maier K, Comploj E, Lodde M, Berner L, Lusuardi L et al. uCyt+/ImmunoCyt in the detection of recurrent urothelial carcinoma: an update on 1991 analyses. Cancer 2006;108:60-5.